EGFR and breast cancer: In this study, we found that osimertinib, the latest third‐generation EGFR inhibitor, significantly inhibited BC cell proliferation, colony formation and the expression of EGFR and its downstream signaling pathways (Figure 1A,B and Figure S1A–D), indicating that osimertinib may be a potential targeted drug for the treatment of BC.